Hercules Capital, Inc. (HCX) - Q2 2018 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2018. Hercules Capital, Inc. is an internally managed, non-diversified closed-end management investment company regulated as a Business Development Company (BDC) under the Investment Company Act of 1940. The Company focuses on providing senior secured loans to high-growth, venture capital-backed companies in technology, life sciences, and sustainable/renewable technology sectors. It also operates two Small Business Investment Companies (SBICs), Hercules Technology II, L.P. and Hercules Technology III, L.P.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2018 | Six Months Ended June 30, 2017 |
|---|---|---|
| Total Investment Income | $98.3 million | $94.8 million |
| Net Investment Income | $48.8 million | $48.0 million |
| Net Realized Gain (Loss) | $(13.8) million | $(2.5) million |
| Net Unrealized Appreciation (Depreciation) | $23.0 million | $(17.9) million |
| Net Increase in Net Assets from Operations | $58.0 million | $27.6 million |
| Net Asset Value (NAV) per Share | $10.22 | $9.96 (Dec 31, 2017) |
| Total Assets | $1.79 billion | $1.65 billion (Dec 31, 2017) |
| Total Liabilities | $828.9 million | $813.7 million (Dec 31, 2017) |
| Cash and Cash Equivalents | $59.5 million | $91.3 million (Dec 31, 2017) |
| Weighted Average Debt Outstanding | $813.9 million | $707.3 million |
Material Changes vs. Prior Period
- Portfolio Growth: Total investment portfolio value increased to $1.70 billion from $1.54 billion at year-end 2017, driven by new fundings of $563.7 million.
- Realized Losses: Net realized losses increased significantly to $13.8 million (vs. $2.5 million in 2017), primarily due to write-offs of warrant and equity investments in 13 portfolio companies and debt investments in 3 companies.
- Unrealized Gains: The portfolio recorded $23.0 million in net unrealized appreciation, a reversal from the $17.9 million depreciation in the prior year period. This was driven by reversals of prior impairments and loan repayments.
- Debt Structure: The Company issued $75.0 million in 2025 Notes in April 2018 and redeemed $100.0 million of 2024 Notes. The weighted average cost of debt decreased to 5.8% for the six-month period compared to 6.5% in 2017.
- Operating Expenses: Total operating expenses rose to $49.4 million from $46.9 million, largely due to increased employee compensation and stock-based compensation.
Guidance, Outlook, and Risks
- Outlook: Management continues to focus on originating new investments in technology and life sciences. The Company maintains a variable distribution policy targeting 90-100% of taxable income.
- Distributions: A quarterly distribution of $0.31 per share was declared on July 25, 2018, payable August 20, 2018. This marks the 52nd consecutive distribution since the IPO.
- Liquidity: As of June 30, 2018, the Company had $221.2 million in available liquidity, including $59.5 million in cash and $161.7 million in available borrowing capacity under credit facilities (Wells and Union Bank).
- Risks:
- Valuation Risk: Approximately 94.9% of assets are valued using Level 3 inputs (unobservable), requiring significant management judgment.
- Credit Risk: Two debt investments were on non-accrual status with a cumulative cost of $2.8 million. The weighted average investment grading declined slightly to 2.21.
- Regulatory Risk: Compliance with BDC asset coverage requirements and RIC tax status is critical; failure could impact distribution ability.
Key Facts for Investor Verification
- NAV vs. Market Price: Verify the current market price relative to the reported NAV of $10.22 to assess the discount/premium.
- Realized Loss Drivers: Review the specific portfolio companies written off to understand the nature of the $13.8 million realized loss.
- Debt Maturity Wall: Confirm the repayment schedule for the $190.2 million in SBA debentures, noting the full redemption of HT II debentures occurred in July 2018 (subsequent event).
- Unfunded Commitments: Note the $129.7 million in unfunded contractual commitments available at the request of portfolio companies.
- Equity Offering: Verify the impact of the June 2018 equity offering ($81.3 million net proceeds) on share count and dilution.